vs

Side-by-side financial comparison of ARDELYX, INC. (ARDX) and Energy Recovery, Inc. (ERII). Click either name above to swap in a different company.

ARDELYX, INC. is the larger business by last-quarter revenue ($125.2M vs $66.9M, roughly 1.9× Energy Recovery, Inc.). On growth, ARDELYX, INC. posted the faster year-over-year revenue change (7.8% vs -0.3%). Over the past eight quarters, ARDELYX, INC.'s revenue compounded faster (30.8% CAGR vs 8.1%).

Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.

Energy Recovery Inc. is an American manufacturer of energy recovery devices for water and CO2 refrigeration industries.

ARDX vs ERII — Head-to-Head

Bigger by revenue
ARDX
ARDX
1.9× larger
ARDX
$125.2M
$66.9M
ERII
Growing faster (revenue YoY)
ARDX
ARDX
+8.1% gap
ARDX
7.8%
-0.3%
ERII
Faster 2-yr revenue CAGR
ARDX
ARDX
Annualised
ARDX
30.8%
8.1%
ERII

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ARDX
ARDX
ERII
ERII
Revenue
$125.2M
$66.9M
Net Profit
$26.9M
Gross Margin
67.2%
Operating Margin
46.8%
Net Margin
40.2%
Revenue YoY
7.8%
-0.3%
Net Profit YoY
14.7%
EPS (diluted)
$0.00
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARDX
ARDX
ERII
ERII
Q1 26
$125.2M
Q4 25
$125.2M
$66.9M
Q3 25
$110.3M
$32.0M
Q2 25
$97.7M
$28.1M
Q1 25
$74.1M
Q4 24
$116.1M
$67.1M
Q3 24
$98.2M
$38.6M
Q2 24
$73.2M
$27.2M
Net Profit
ARDX
ARDX
ERII
ERII
Q1 26
Q4 25
$-407.0K
$26.9M
Q3 25
$-969.0K
$3.9M
Q2 25
$-19.1M
$2.1M
Q1 25
$-41.1M
Q4 24
$4.6M
$23.5M
Q3 24
$-809.0K
$8.5M
Q2 24
$-16.5M
$-642.0K
Gross Margin
ARDX
ARDX
ERII
ERII
Q1 26
Q4 25
91.3%
67.2%
Q3 25
96.4%
64.2%
Q2 25
87.3%
64.0%
Q1 25
83.4%
Q4 24
84.3%
70.2%
Q3 24
84.0%
65.1%
Q2 24
87.1%
64.6%
Operating Margin
ARDX
ARDX
ERII
ERII
Q1 26
Q4 25
4.1%
46.8%
Q3 25
4.2%
11.4%
Q2 25
-14.7%
5.3%
Q1 25
-49.0%
Q4 24
7.0%
38.2%
Q3 24
2.3%
18.3%
Q2 24
-18.6%
-7.4%
Net Margin
ARDX
ARDX
ERII
ERII
Q1 26
Q4 25
-0.3%
40.2%
Q3 25
-0.9%
12.1%
Q2 25
-19.5%
7.3%
Q1 25
-55.5%
Q4 24
4.0%
35.0%
Q3 24
-0.8%
22.0%
Q2 24
-22.5%
-2.4%
EPS (diluted)
ARDX
ARDX
ERII
ERII
Q1 26
$0.00
Q4 25
$-0.01
$0.49
Q3 25
$0.00
$0.07
Q2 25
$-0.08
$0.04
Q1 25
$-0.17
Q4 24
$0.01
$0.40
Q3 24
$0.00
$0.15
Q2 24
$-0.07
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARDX
ARDX
ERII
ERII
Cash + ST InvestmentsLiquidity on hand
$264.7M
$75.2M
Total DebtLower is stronger
$202.8M
Stockholders' EquityBook value
$166.9M
$206.2M
Total Assets
$501.6M
$231.5M
Debt / EquityLower = less leverage
1.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARDX
ARDX
ERII
ERII
Q1 26
$264.7M
Q4 25
$68.0M
$75.2M
Q3 25
$42.7M
$70.4M
Q2 25
$90.0M
$79.5M
Q1 25
$30.8M
Q4 24
$64.9M
$78.0M
Q3 24
$47.4M
$118.6M
Q2 24
$41.9M
$101.0M
Total Debt
ARDX
ARDX
ERII
ERII
Q1 26
$202.8M
Q4 25
$202.8M
Q3 25
$202.1M
Q2 25
$201.4M
Q1 25
$151.3M
Q4 24
$150.9M
Q3 24
$100.7M
Q2 24
$100.2M
Stockholders' Equity
ARDX
ARDX
ERII
ERII
Q1 26
$166.9M
Q4 25
$166.9M
$206.2M
Q3 25
$154.3M
$180.8M
Q2 25
$139.5M
$185.2M
Q1 25
$145.7M
Q4 24
$173.3M
$210.0M
Q3 24
$158.3M
$233.9M
Q2 24
$147.0M
$218.5M
Total Assets
ARDX
ARDX
ERII
ERII
Q1 26
$501.6M
Q4 25
$501.6M
$231.5M
Q3 25
$486.2M
$209.6M
Q2 25
$466.8M
$212.3M
Q1 25
$410.2M
Q4 24
$435.8M
$242.8M
Q3 24
$367.9M
$262.7M
Q2 24
$343.5M
$249.0M
Debt / Equity
ARDX
ARDX
ERII
ERII
Q1 26
1.21×
Q4 25
1.21×
Q3 25
1.31×
Q2 25
1.44×
Q1 25
1.04×
Q4 24
0.87×
Q3 24
0.64×
Q2 24
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARDX
ARDX
ERII
ERII
Operating Cash FlowLast quarter
$7.1M
Free Cash FlowOCF − Capex
$6.4M
FCF MarginFCF / Revenue
9.6%
Capex IntensityCapex / Revenue
1.0%
Cash ConversionOCF / Net Profit
0.26×
TTM Free Cash FlowTrailing 4 quarters
$15.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARDX
ARDX
ERII
ERII
Q1 26
Q4 25
$21.0M
$7.1M
Q3 25
$365.0K
$-3.1M
Q2 25
$-25.3M
$4.1M
Q1 25
$-38.5M
Q4 24
$9.8M
$9.0M
Q3 24
$501.0K
$-3.0M
Q2 24
$-19.4M
$8.1M
Free Cash Flow
ARDX
ARDX
ERII
ERII
Q1 26
Q4 25
$20.6M
$6.4M
Q3 25
$209.0K
$-3.5M
Q2 25
$-26.0M
$4.0M
Q1 25
$-38.8M
Q4 24
$9.2M
$8.9M
Q3 24
$364.0K
$-3.2M
Q2 24
$-19.5M
$7.9M
FCF Margin
ARDX
ARDX
ERII
ERII
Q1 26
Q4 25
16.4%
9.6%
Q3 25
0.2%
-10.9%
Q2 25
-26.6%
14.3%
Q1 25
-52.3%
Q4 24
7.9%
13.2%
Q3 24
0.4%
-8.2%
Q2 24
-26.7%
28.9%
Capex Intensity
ARDX
ARDX
ERII
ERII
Q1 26
Q4 25
0.3%
1.0%
Q3 25
0.1%
1.1%
Q2 25
0.7%
0.5%
Q1 25
0.4%
Q4 24
0.5%
0.2%
Q3 24
0.1%
0.4%
Q2 24
0.2%
0.7%
Cash Conversion
ARDX
ARDX
ERII
ERII
Q1 26
Q4 25
0.26×
Q3 25
-0.81×
Q2 25
2.02×
Q1 25
Q4 24
2.11×
0.38×
Q3 24
-0.35×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARDX
ARDX

IBSRELA$86.6M69%
XPHOZAH$27.8M22%
Product supply revenue$9.4M8%
Non-cash royalty revenue related to the sale of future royalties$1.4M1%
Licensing revenue$23.0K0%

ERII
ERII

Water Segment$38.6M58%
Other$11.0M16%
Original Equipment Manufacturer$10.6M16%
Aftermarket$6.6M10%

Related Comparisons